KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses: 2009-2025

Historic Other Accumulated Expenses for Vertex Pharmaceuticals (VRTX) over the last 15 years, with Sep 2025 value amounting to $441.5 million.

  • Vertex Pharmaceuticals' Other Accumulated Expenses rose 23.46% to $441.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $441.5 million, marking a year-over-year increase of 23.46%. This contributed to the annual value of $363.0 million for FY2024, which is 31.15% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Other Accumulated Expenses is $441.5 million, which was up 3.78% from $425.4 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $648.6 million during Q1 2024, with a 5-year trough of $201.4 million in Q3 2021.
  • Its 3-year average for Other Accumulated Expenses is $410.3 million, with a median of $386.4 million in 2025.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Other Accumulated Expenses soared by 72.04% in 2024, and later crashed by 40.43% in 2025.
  • Vertex Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $268.4 million in 2021, then climbed by 16.06% to $311.5 million in 2022, then soared by 69.25% to $527.2 million in 2023, then crashed by 31.15% to $363.0 million in 2024, then rose by 23.46% to $441.5 million in 2025.
  • Its Other Accumulated Expenses was $441.5 million in Q3 2025, compared to $425.4 million in Q2 2025 and $386.4 million in Q1 2025.